BrightOwl Loader Loading

PhD on PK/PD modeling of therapeutic monoclonal antibodies for therapeutic drug monitoring Leuven Belgium,  

Posted on : 02 June 2017

Project Description

ProjectAnti-tumornecrosis factor-alfa (anti-TNF) drugs are being used for the treatment of patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel diseases. These biological drugs are able to induce and maintain remission, but inter- and intra-individual variability in the pharmacokinetic (PK) processes lead to a variable therapeutic response. The development of an immune response against these drugs (i.e. the development of anti-drug antibodies (ADA)), is one of the many factors that can influence the PK of the biologicals and may give rise to loss of response.The Laboratory for Therapeutic and Diagnostic Antibodies has developed assays to measure serum concentrations of anti-TNF drugs (infliximab, adalimumab,golimumab and etanercept), anti-integrin drugs (vedolizumab) and anti-interleukin drugs (ustekinumab, secukinumab), and to quantify the immune response against these drugs (ADA). These assays are used for therapeutic drug monitoring (TDM) and they are the basis to support clinical decision-making (Dreesen E et al., Curr Drug Targets. 2016; Detrez I et al.,Clin Sci 2017).This project includes: The systematic collection


3000 Leuven Belgium

Find a Job Find Candidates

Most Recent Searches

Most Famous Searches

You might also like